BIOL - バイオレ―ズ (Biolase Inc.) バイオレ―ズ



symbol BIOL
会社名 Biolase Inc (バイオレ―ズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Medical/Dental Instruments  
業種 先端医療機器_テクノロジ―   医療関連(Health Care)
概要 事業概要 バイオレーサー・テクノロジー(BIOLASE Technology Inc)は歯科用レーザー会社。同社は医療技術会社であり、歯科用レーザーの開発・製造・販売、及び技術中心型の歯科用イメージング機器と製品の流通・販売に従事する。同社のレーザー製品は疼痛の減少、回復時間の加速を実現できる技術を採用した。同社の製品は美容および外科アプリケーションを含む一連の歯科治療を行う歯科用レーザーシステム、及び一連の歯科用イメージング機器を含む。他の開発中の製品は眼科や他の医療およびコンシューマ市場を目当てにする。   バイオレ―ズは米国の歯科・医療機器メ―カ―。主要製品はレ―ザ―エネルギ―と水を組み合わせたレ―ザ―システムWaterLase(ウォ―タ―レ―ズ)。患者にとってより安全で痛みを軽減した治療法を提供。またレ―ザ―ホワイトニングと治療の為のEpichやワイヤレス歯科レ―ザ―iLase、動物用レ―ザ―Epic Vシリ―ズなども展開。   BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine. BIOLASE's products advance the practice of dentistry and medicine for patients and healthcare professionals. BIOLASE's proprietary laser products incorporate approximately 271 patented and 40 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times. BIOLASE's innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients. BIOLASE's principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. BIOLASE has sold over 41,200 laser systems to date in over 80 countries around the world. Laser products under development address BIOLASE's core dental market and other adjacent medical and consumer applications.
本社所在地 4 Cromwell Irvine CA 92618 USA
代表者氏名 Jonathan T. Lord ジョナサン・T・ロード
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 949-361-1200
設立年月日 31809
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 195人
EBITDA EBITDA(百万ドル) -17.70500
終値(lastsale) 1.53
時価総額(marketcap) 31513258.53
時価総額 時価総額(百万ドル) 32.13117
売上高 売上高(百万ドル) 45.61400
企業価値(EV) 企業価値(EV)(百万ドル) 29.31617
当期純利益 当期純利益(百万ドル) 2.71400
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 BIOLASE Inc revenues decreased 6% to $22.2M. Net loss applicable to common stockholders decreased 20% to $9.9M. Revenues reflect United States segment decrease of 14% to $12.9M. Lower net loss reflects others decrease of 20% to $2.5M (expense) Sales and Marketing - Balancing value decrease of 3% to $8.3M (expense).



   Sonendo unit PIPStek files patent infringement lawsuit against Biolase  2023/01/04 21:31:49 Seeking Alpha
Sonendo (SONX) on Wednesday said its unit PIPStek had filed a patent infringement lawsuit against maker of dental lasers Biolase (BIOL). Read more on the lawsuit here.
   PIPStek LLC, a Subsidiary of Sonendo, Files Patent Infringement Lawsuit Against BIOLASE  2023/01/04 21:20:00 Wallstreet:Online
Sonendo, Inc. (NYSE: SONX), a leading dental technology company and developer of the GentleWave System, today announced that its subsidiary PIPStek LLC has filed a patent infringement lawsuit against BIOLASE, Inc. in the U.S. District Court for the District of Delaware. In the lawsuit, PIPStek asserts infringement of PIPStek’s US patents 11,426,239 and 11,350,993 by BIOLASE’s Waterlase laser.
   Is the BIOLASE Inc. (NASDAQ:BIOL) stock an investment opportunity?  2022/12/02 17:00:00 US Post News
BIOLASE Inc. (BIOL)’s stock has witnessed a price declined of -11.86% from the previous close with its current price standing at $0.85. Its current price is -93.86% under its 52-week high of $13.83 and -7.61% more than its 52-week low of $0.92. Based on the past 30-day period, the stock price is -57.30% below the […]
   Looking Into Biolase''s Recent Short Interest  2022/11/28 15:23:10 Benzinga
Biolase''s (NASDAQ: BIOL ) short percent of float has risen 16.13% since its last report. The company recently reported that it has 126 thousand shares sold short , which is 1.8% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.7 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price … Full story available on
   BIOLASE Inc. (NASDAQ:BIOL) stock: You might be surprised  2022/11/23 17:00:00 US Post News
Currently, BIOLASE Inc.’s (BIOL) stock is trading at $1.01, marking a fall of -37.27% from last night’s close. At this price, the stock is -92.70% below its 52-week high of $13.83 and -27.86% above its 52-week low of $1.40. Based on the past 30-day period, the stock price is -50.95% below the high and +6.19% […]
   BIOLASE amends senior secured term loan with SWK Funding  2022/07/01 09:38:09 Seeking Alpha
BIOLASE (BIOL) has amended its senior secured term loan with SWK Funding LLC by extending the interest-only period of the loan by two quarters to November 2023 and reduces the…
   Biolase trades in red on pricing $6.5M in stock and pre-funded warrants offering  2022/06/28 12:49:57 Seeking Alpha
Biolase (BIOL) plunged 13.8% lower in premarket trade after it entered into a securities purchase agreement with a single institutional investor to purchase ~$6.5M of its stock…
LAKE FOREST, Calif. , June 27, 2022 /PRNewswire/ -- BIOLASE , Inc. (NASDAQ: BIOL ), the global leader in dental lasers, announced today that it has partnered with Project HOME , an organization that provides dental services to patients from their first birthday to adulthood. Project HOME''s Healthcare Services is a Federally Qualified Health Center (FQHC) and supports health care services, regardless of a person''s ability to pay for the services, in Philadelphia. The mission of Project HOME is to empower adults, children, and families to break the cycle of homelessness and poverty, alleviate the underlying causes of poverty, and enable individuals to attain their fullest potential as individuals and as members of the broader society. Project HOME strives to create a safe and respectful environment to support individuals struggling with self-esteem, recovery, confidence, as well as mental and physical health. Project HOME''s dental services are part of a patient-centered, integrated health care service model, where many dental patients are also primary care patients.
   Dental Equipment Market to reach $12 billion in 2030 with a CAGR of 7.7 %. The rise in Geriatric Population and Medical Tourism to drive the Market  2022/05/31 13:26:34 Benzinga
New York, United States, May 31, 2022 (GLOBE NEWSWIRE) -- Dental instruments are tools used to cure, examine, manipulate, and restore any oral-related diseases. Based on Product Type, the dental systems and parts segment held the largest share of almost 39.9% of the entire market in 2020. Moreover, on a regional basis, North America possessed the largest Dental Equipment Market share of around 38.2% in 2020 and is expected to rise with a steady CAGR during the forecasted period. To get a first-hand overview of the report, Request a Sample at The segmentation analysis of the latest report published by Strategic Market Research on the Dental Equipment Market is as follows: By Product Therapeutic Dental Equipment Dental Operatory & Treatment Center Equipment Dental Units Instrument Delivery Systems Dental Chairs Dental Handpieces Dental Light-curing Equipment Other Dental Operatory & Treatment Center Equipment General Equipment CAD/CAM Systems Electrosurgical Systems Casting Machines Ceramic Furnaces Dental Lasers Soft-tissue Lasers Diode Lasers Carbon Dioxide (CO2) Lasers Nd:YAG Lasers All-Tissue (Hard/Soft) Lasers Er:YAG Lasers Er,Cr:YSGG Lasers Diagnostic Systems Extraoral Imaging Systems Panoramic Systems 3D CBCT Systems Panoramic & Cephalometric Systems Intraoral Imaging Systems Intraoral X-Ray Systems Intraoral Sensors Intraoral Photostimulable Phosphor Systems Intraoral Cameras Dental Imaging Software Based on End-User · Hospitals and Clinics · Dental Academic & Research Institutes · Other End Users Regions North America Europe Asia-Pacific LAMEA Make a Direct Purchase of the latest Dental Equipment Market Report published in the month of May 2022.
   Data Breach at Biolase, Inc. Results in Compromised Consumer Data  2022/05/26 14:06:27 JD Supra
Recently, Biolase, Inc. reported that an unauthorized party gained access to the company’s computer network. As a result, the company confirmed that the sensitive consumer data contained on the network was compromised…. By: Console and Associates, P.C.
   BIOLASE Inc. (NASDAQ: BIOL) Up 1.55%: This Is What Analysts Now Expect  2022/04/01 13:00:00 Stocks Register
BIOLASE Inc. (NASDAQ:BIOL) shares, rose in value on Thursday, 03/31/22, with the stock price up by 1.55% to the previous day’s close as strong demand from buyers drove the stock to $0.35. Actively observing the price movement in the last trading, the stock closed the session at $0.35, falling within a range of $0.3431 and … BIOLASE Inc. (NASDAQ: BIOL) Up 1.55%: This Is What Analysts Now Expect Read More »
   Is BIOLASE Inc. (NASDAQ: BIOL) Stock Set To Rise More?  2022/03/23 12:00:00 Marketing Sentinel
In the last trading session, 1.3 million BIOLASE Inc. (NASDAQ:BIOL) shares changed hands as the company’s beta touched 1.40. With the company’s per share price at $0.35 changed hands at $0.0 or 0.49% during last session, the market valuation stood at $60.23M. BIOL’s last price was a discount, traded about -194.29% off its 52-week high … Is BIOLASE Inc. (NASDAQ: BIOL) Stock Set To Rise More? Read More »
   BIOLASE: Bad News Across The Board - Sell  2022/03/21 15:09:29 Seeking Alpha
   BIOLASE, Inc. (BIOL) CEO John Beaver On Q4 2021 Results - Earnings Call Transcript  2022/03/17 22:44:10 Seeking Alpha
   BIOLASE, Inc. 2021 Q4 - Results - Earnings Call Presentation  2022/03/17 21:29:58 Seeking Alpha

 関連キーワード  (先端医療機器_テクノロジ― 米国株 バイオレ―ズ BIOL Biolase Inc.)


 twitter  (公式ツイッターやCEOツイッターなど)